Collin Blakely

Collin Blakely is a physician-scientist at the University of California San Francisco, specializing in lung cancer treatment and research. He earned a BS in Molecular and Cellular Biology from the University of Washington and dual MD/PhD degrees from the University of Pennsylvania's Medical Scientist Training Program.

• Education:
  • BS, Molecular Biology, University of Washington (1997)
  • PhD, Cell and Molecular Biology, University of Pennsylvania (2006)
  • MD, Medicine, University of Pennsylvania (2007)

His research focuses on molecular mechanisms of lung cancer resistance to EGFR/ALK inhibitors and developing targeted therapies to overcome these challenges. He investigates drug-tolerant persister cells, genomic instability, and immune checkpoint inhibition strategies.

Key publication trends include collaborations on clinical trials (osimertinib, sitravatinib), resistance mechanisms (CTLA4 blockade, MET alterations, RBM10 deficiency), and single-cell transcriptomics for treatment prediction. His work bridges laboratory discoveries to clinical applications in NSCLC.

• Scientific Awards:
  • Damon Runyon Clinical Investigator Award (2018)
  • V Scholar Award (2014)
  • Multiple research grants from lung cancer foundations

Blakely actively contributes to national clinical trials and studies genomic drivers of resistance in Journal of Clinical Oncology, Nature, and other top-tier publications. He collaborates with institutions globally on NSCLC research.